Modernizing Pharmaceutical and Medical Device Manufacturing Regulations: Global Challenges and Transformative Impacts

The regulatory landscape in pharmaceutical and medical device manufacturing is undergoing a seismic transformation driven by an imperative to enhance patient safety and adapt to accelerating technological innovation. Authorities worldwide are shifting away from rigid statutory protocols toward dynamic, risk-based approaches that reflect the rapidly evolving nature of healthcare products. Europe is at the forefront, with its Human Medicine Regulations under revision and the implementation of the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), both of which have introduced comprehensive changes to requirements for clinical evidence, post-market surveillance, and lifecycle management. Regulatory bodies across the globe, including the FDA, are similarly recalibrating their frameworks to address both global market demands and technological advancements. Yet, this complex paradigm shift raises new questions about regulatory harmonization, market access, operational feasibility, and global competitiveness.

Recent studies have highlighted that innovations such as Artificial Intelligence (AI), Software as a Medical Device (SaMD), and Advanced Therapy Medicinal Products (ATMPs) are often faster to market than regulators can adapt legal frameworks. New approaches like the EU’s upcoming AI Act and the FDA’s “Total Product Lifecycle” paradigm strive to manage these technologies, but implementation remains inconsistent and presents ongoing challenges. Bottlenecks in notified body capacity, complex data transparency stipulations, and economic pressures on small and medium-sized enterprises (SMEs) have all been documented as key hurdles. The integration of sustainability and supply chain resilience, spurred by policies such as the EU Green Deal and the Corporate Sustainability Reporting Directive (CSRD), further complicate compliance and operational viability for manufacturers. Gaps persist in understanding the broader impacts of these developments on availability, affordability, global market parity, and patient outcomes.

This Research Topic aims to critically assess whether emerging pharmaceutical and medical device regulations serve as catalysts for higher standards and innovation or inadvertently act as barriers to entry and diversity in the market. The central objectives are to examine the practical impacts of major legislative overhauls, explore the interplay between regulatory oversight and technological innovation, and identify whether current approaches support or hinder sustainable, patient-centered healthcare delivery. Key questions include how real-world evidence and adaptive frameworks can close the innovation-regulation gap, the effects on small manufacturers, and strategies for achieving alignment across global markets.

Given the international scope of regulatory shifts, contributions that focus specifically on the European Union as well as those addressing broader global dynamics are welcome. We seek studies that provide insight into operational, economic, and patient care outcomes under the current and evolving regulatory landscape. To gather further insights into the impact and challenges of emerging regulatory frameworks in pharmaceuticals and medical devices, we welcome articles addressing, but not limited to, the following themes:

• Comparative analyses of international regulatory approaches and harmonization efforts

• The integration and impact of real-world evidence (RWE) and post-market surveillance requirements

• Challenges and opportunities for SMEs under the new regimes

• The regulation of disruptive technologies (AI, SaMD, ATMPs, etc.)

• Effects on legacy product availability and access to innovative therapies

• Strategies for supply chain resilience and sustainability reporting

• Policy developments linking regulatory oversight with patient safety and quality improvement

We invite all manuscript types, including original research articles, case studies, perspectives, commentaries, and critical reviews.

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Editorial
• FAIR² Data
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• ... View all formats

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Article types

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Editorial
• FAIR² Data
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• Opinion
• Original Research
• Perspective
• Policy and Practice Reviews
• Policy Brief
• Review
• Study Protocol
• Systematic Review
• Technology and Code

Keywords: pharmaceutical, medical devices, manufacturing, distribution, quality, safety

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.